Opinion statement
Gliomatosis cerebri (GC) is an intriguing disease for several reasons. First, it is difficult to draw the border between GC and diffuse gliomas. In this regard, GC could represent the most invasive form of diffuse gliomas. Second, both in terms of histologic grading and clinical course, GC is a heterogeneous disease, ranging from rapidly evolving to slowly and somewhat indolent forms. Because of the extensive spread of the disease, surgery—outside a biopsy for diagnosis—is rarely indicated in gliomatosis cerebri. Therapeutic options include radiotherapy, generally involving the whole brain, and chemotherapy with temozolomide or nitrosoureas. Because of the rarity of the disease, no trial comparing these two modalities has been undertaken so far. Decision is, therefore, based on small retrospective noncomparative studies and expert opinions. On one hand, there is a rationale to postpone the whole brain radiotherapy because of late neurotoxicity, but on the other hand, there is also the risk that an aggressive disease evolves to intracranial hypertension making the radiotherapy hazardous or even impossible. As a consequence, the patient would lose the opportunity to receive a potentially effective treatment. In this decision, the evaluation of histologic data together with clinical and radiologic features, performance status, and molecular profile may be of help. Because radiotherapy usually involves large volumes of the brain, chemotherapy is generally preferred up front in patients with a slowly evolving disease. Conversely, in patients with rapidly (ie, over few weeks) evolving disease with neurologic deficits or when histologic features of glioblastoma are evident, whole brain radiotherapy (45 Gy with 1.8 Gy fractions), alone or associated with concomitant temozolomide, is often preferred. The value of advanced of magnetic resonance imaging and positron emission tomography techniques to predict outcome and monitoring the treatment still remains to be defined.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G. Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol. 1985;4:135–48.
Jennings MT, Frenchman M, Shehab T, Johnson MD, Creasy J, LaPorte K, et al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol. 1995;10:37–45.
Kim DG, Yang HJ, Park IA, Chi JG, Jung HW, Han DH, et al. Gliomatosis cerebri: clinical features, treatment, and prognosis. Acta Neurochir (Wien). 1998;140:755–62.
Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, et al. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neuro-Oncol. 2006;76:201–5.
Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR. Presentation patterns and outcome of gliomatosis cerebri. Oncol Lett. 2012;3:209–13. An interesting report of patterns at presentation in GC.
Levin N, Gomori JM, Siegal T. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology. 2004;63:354–6.
Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, et al. Initial chemotherapy in gliomatosis cerebri. Neurology. 2004;63:270–5.
Glas M, Rasch K, Wiewrodt D, Weller M, Herrlinger U. Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology. 2008;75:182–5.
Gottesman M, Laufer H, Patel M. Gliomatosis cerebri: a case report. Clin Neuropathol. 1991;10:303–5.
Bertrand E, Kryst-Widzgowska T, Baranska M. Gliomatosis cerebri at the 17-year-old girl — correlations of histological, CT and MRI appearance. Folia Neuropathol. 1994;32:245–9.
del Carpio-O'Donovan R, Korah I, Salazar A, Melancon D. Gliomatosis cerebri. Radiology. 1996;198:831–5.
Slee M, Pretorius P, Ansorge O, Stacey R, Butterworth R. Parkinsonism and dementia due to gliomatosis cerebri mimicking sporadic Creutzfeldt-Jakob disease (CJD). J Neurol Neurosurg Psychiatry. 2006;77:283–4.
Molho ES. Gliomatosis cerebri may present as an atypical parkinsonian syndrome. Mov Disord. 2004;19:341–4.
Felsberg GJ, Glass JP, Tien RD, McLendon R. Gliomatosis cerebri presenting with optic nerve involvement: MRI. Neuroradiology. 1996;38:774–7.
Ross IB, Robitaille Y, Villemure JG, Tampieri D. Diagnosis and management of gliomatosis cerebri: recent trends. Surg Neurol. 1991;36:431–40.
Shin YM, Chang KH, Han MH, Myung NH, Chi JG, Cha SH, et al. Gliomatosis cerebri: comparison of MR and CT features. Am J Roentgenol. 1993;161:859–62.
Hejazi N, Witzmann A, Hergan K. Gliomatosis cerebri: intra vitam stereotactic determination in two cases and review of the literature. Br J Neurosurg. 2001;15:396–401.
Peretti-Viton P, Brunel H, Chinot O, Daniel C, Barrie M, Bouvier C, et al. Histological and MR correlations in Gliomatosis cerebri. J Neuro-Oncol. 2002;59:249–59.
Kaloshi G, Guillevin R, Martin-Duverneuil N, Laigle-Donadey F, Psimaras D, Marie Y, et al. Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri. Neurology. 2009;73:445–9.
Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg. 2003;98:269–76.
Saraf-Lavi E, Bowen BC, Pattany PM, Sklar EM, Murdoch JB, Petito CK. Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels. Am J Neuroradiol. 2003;24:946–51.
Mohana-Borges AV, Imbesi SG, Dietrich R, Alksne J, Amjadi DK. Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri: a unique pattern of normal choline but elevated Myo-inositol metabolite levels. J Comput Assist Tomogr. 2004;28:103–5.
Yu A, Li K, Li H. Value of diagnosis and differential diagnosis of MRI and MR spectroscopy in gliomatosis cerebri. Eur J Radiol. 2006;59:216–21.
Inoue T, Fujimura M, Kumabe T, Nakasato N, Higano S, Tominaga T. Combined three-dimensional anisotropy contrast imaging and magnetoencephalography guidance to preserve visual function in a patient with an occipital lobe tumor. Minim Invasive Neurosurg. 2004;47:249–52.
Akai H, Mori H, Aoki S, Masutani Y, Kawahara N, Shibahara J, et al. Diffusion tensor tractography of gliomatosis cerebri: fiber tracking through the tumor. J Comput Assist Tomogr. 2005;29:127–9.
Yang S, Wetzel S, Law M, Zagzag D, Cha S. Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri. Am J Neuroradiol. 2002;23:350–5.
Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A, et al. Gliomatosis cerebri evaluated by 18Falpha-methyl tyrosine positron-emission tomography. Neuroradiology. 2003;45:700–7.
Senatus PB, McClelland III S, Tanji K, Khandji A, Huang J, Feldstein N. The transformation of pediatric gliomatosis cerebri to cerebellar glioblastoma multiforme presenting as supra- and infratentorial acute disseminated encephalomyelitis. Case report. J Neurosurg. 2005;102:72–7.
Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M, et al. Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neuro-Oncol. 2011;105:219–24. The first study proposing a molecular stratification of gliomatosis cerebri.
Kaloshi G, Everhard S, Laigle-Donadey F, Marie Y, Navarro S, Mokhtari K, et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology. 2007;70:590–5.
Vates GE, Chang S, Lamborn KR, Prados M, Berger MS. Gliomatosis cerebri: a review of 22 cases. Neurosurgery. 2003;53:261–71. discussion 271.
Chappe C, Riffaud L, Treguier C, Carsin-Nicol B, Veillard D, Chiforeanu DC, et al. Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multi-center study of 14 cases. Childs Nerv Syst. 2013;29:565–71. The first multi-center study on gliomatosis in the pediatric population.
Girard N, Wang ZJ, Erbetta A, Sutton LN, Phillips PC, Rorke LB, et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology. 1998;40:121–5.
Bendszus M, Warmuth-Metz M, Klein R, Burger R, Schichor C, Tonn JC, et al. MR spectroscopy in gliomatosis cerebri. Am J Neuroradiol. 2000;21:375–80.
Pyhtinen J. Proton MR, spectroscopy in gliomatosis cerebri. Neuroradiology. 2000;42:612–5.
Guzman-de-Villoria JA, Sanchez-Gonzalez J, Munoz L, Reig S, Benito C, Garcia-Barreno P, et al. 1H MR spectroscopy in the assessment of gliomatosis cerebri. Am J Roentgenol. 2007;188:710–4.
Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1137–46.
Cozad SC, Townsend P, Morantz RA, Jenny AB, Kepes JJ, Smalley SR. Gliomatosis cerebri. Results with radiation therapy. Cancer. 1996;78:1789–93.
Elshaikh MA, Stevens GH, Peereboom DM, Cohen BH, Prayson RA, Lee SY, et al. Gliomatosis cerebri: treatment results with radiotherapy alone. Cancer. 2002;95:2027–31.
Glas M, Bahr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol. 2011;70:445–53. The first phase II trial exploring chemotherapy in GC alone as initial treatment.
Chen S, Tanaka S, Giannini C, Morris J, Yan ES, Buckner J, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neuro-Oncol. 2013;112:267–75.
Louis E, Keime-Guibert F, Delattre JY, Sanson M. Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology. 2003;60:151.
Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2012;12:1078–82.
Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, et al. A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res. 2013;18:5071–80.
Herrlinger U, Felsberg J, Kuker W, Bornemann A, Plasswilm L, Knobbe CB, et al. Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol. 2002;52:390–9.
Piccirilli M, Landi A, Salvati M. Gliomatosis cerebri treatment in 11 elderly patients. J Exp Clin Cancer Res. 2006;25:183–7.
Rudà R, Laguzzi E, Pace A, Carapella CM, Riva M, Salvati M, et al. Temozolomide in primary gliomatosis cerebri: final results of a retrospective study of the AINO (Italian Association of Neuro-Oncology). Neuro Oncol (Abstracts from the Eighth Congress of the European Association of Neuro-Oncology). 2008;10:1069.
Kong DS, Kim ST, Lee JI, Suh YL, Lim do H, Kim WS, et al. Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer. 2012;10:424. An interesting report on the role of adjuvant chemotherapy in GC.
Fukushima Y, Nakagawa H, Tamura M. Combined surgery, radiation, and chemotherapy for oligodendroglial gliomatosis cerebri. Br J Neurosurg. 2004;18:306–10.
Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. Clin Neurol Neurosurg. 2012;114:299–306.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Compliance with Ethics Guidelines
Conflict of Interest
Roberta Rudà declares that she has no conflict of interest.
Luca Bertero declares that she has no conflict of interest.
Marc Sanson declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Neuro-oncology
Rights and permissions
About this article
Cite this article
Rudà, R., Bertero, L. & Sanson, M. Gliomatosis Cerebri: A Review. Curr Treat Options Neurol 16, 273 (2014). https://doi.org/10.1007/s11940-013-0273-2
Published:
DOI: https://doi.org/10.1007/s11940-013-0273-2